banner
 
bar
program slides
bar
 
 

Multiple Sclerosis in the
Managed Care Setting

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period May 22, 2012 through May 22, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 10 segments totaling 3 hours and 17 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form; and 4) print out your CME certificate

Estimated Time to Complete Educational Activity

3.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of managing multiple sclerosis.

Release Date

May 22, 2012

Expiration Date

May 22, 2014

Intended Audience

This complimentary CME educational activity is designed for all neurology-focused physicians, nurses, NPs, academicians, pharmacists, researchers, investigators, and program directors managing, referring, and/or consulting on patients with multiple sclerosis. The program will emphasize content, topics, issues, and clinical challenges/solutions encountered by clinicians and pharmacists practicing in a managed care setting.

Registration

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoThis activity is supported by an
educational grant from
Teva Neuroscience

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosure

FRED LUBLIN, MD – Program Chairman
Saunders Family Professor of Neurology
Mount Sinai School of Medicine
Director
The Corinne Goldsmith Dickinson Center for MS
New York, NY

Consultant: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis;
Pfizer; Teva Neuroscience; Genmab; Medicinova; Actelion; Allozyne, Sanofi-
Aventis, Acorda, Questcor, Avanir, Roche, Celgene, Abbott, MorphpSys: Johnson
& Johnson, Revalesio; Coronado Bioscience, Genzyme, MedImmune
Grant/Research Support: Acorda Therapeutics, Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva
Neuroscience, Inc.; Genzyme; Sanofi: Celgene; NIH; NMSS
Current FInancial/Stock Ownership: Cognition Pharmaceuticals, Inc



BRIAN STEINGO, MD
Director, Fort Lauderdale MS Center
Sunrise Medical Group
Pompano Beach, FL

Consultant: Novartis, Biogen, Teva, Acorda, Questcor
Speaker's Bureau: Novartis, Biogen, Teva, Acorda, Questcor
Grant/Research Support: Novartis, Biogen, Sanofi



DANIEL KANTOR, MD

Medical Director
Neurologique Foundation
President
Florida Society of Neurology
Ponte Vedra, FL

Consultant: Allergan, Acorda, Avanir, Bayer, Biogen, EMD Serono, Teva, Questcor, Merz
Speaker's Bureau: Allergan, Acorda, Avanir, Bayer, Biogen, EMD Serono, Teva, Questcor, Merz
Grant/Research Support: Allergan, Acorda, Avanir, Bayer, Biogen, EMD Serono, Teva, Questcor, Merz



RONALD DEBELLIS, PharmD, FCCP
Professor and Chair, Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Colchester, VT

Nothing to disclose

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this educational activity, participants should:

  • Identify the rationale for treating patients with MS with agents shown to act through immunomodulating effects and actions that take place in the central nervous system
  • Understand the established and evolving role of neuroimmunomodulating agents for MS; and, how such agents, including established injectable IMTs, acting on both inflammatory and neurodegenerative dimensions of MS disease progression, may produce different clinical outcome end points than agents acting on inflammatory dimensions of the disease only
  • Understand the role of and comparisons among IMTs used for initial, first-line foundation therapy in MS, with a focus on safety, efficacy, and long-term clinical experience
  • Detail how the possible approval of new MS therapies—including both oral and injectable agents—may change the risk-to-benefit proposition for and influence long-term treatment decisions for MS treatment regimens implemented in the managed care setting
  • Explain the clinical risks and benefits of established, injectable IMTs as compared to emerging agents under evaluation for MS, and how the safety profiles of new agents compare to established platforms with documented long-term safety and LTFU studies showing EDSS stabilization and reduction in relapse rates

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations


bar
program slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

ACT
alemtuzumab
Avonex
Axonal
Azathioprine
Behçet
BENEFIT
betaseron
BEYOND
Brain Atrophy
brain stem
CD4+ T
cerebellum,
spinal cord
cerebral cortex
Cladribine
CHAMPIONS
CHAMPS/ETOMS

Copaxone
Corticosteroids
Cyclophosphamide
daclizumab
Demyelination
DMD
EDSS
EVIDENCE
Fingolimod
Glatiramer acetate
HIV
HTLV-1
Human IgG4IFN b-1a
IFN b-1b
Immunosuppression
Laquinimod
INCOMIN

Interferon
Lesions
Lyme disease
Methotrexate
Mitoxantrone
MRI
Multiple Sclerosis
relapsing-remitting MS
Mycophenolate mofetil
Natalizumab
neuritic transection
neurodegenerative
Neuroimmunomodulating
neuroimmunomodulation
Neurosyphilis
NIMO
NMSS
Novantrone

optic nerves
periventricular
PML
PRECISE
PRISMS
Rebif
REGARD
rituximab
RRMS
Sarcoidosis
Selective adhesion molecule inhibitor
Sjögren syndrome
Statins
Teriflunomide
Tysabri
white matter